Inovio up on positive peer-reviewed data for COVID-19 jab

 

• Inovio Pharmaceuticals (NASDAQ:INO) has climbed 9.0% in the premarket after the medical journal, The Lancet, published the Phase 1 clinical trial data of its COVID-19 vaccine candidate, INO-4800.
• In June, the company announced positive interim Phase 1 data for INO-4800 indicating 94% of immunogenicity of 40 healthy trial participants aged 18 to 50 years.
• According to the journal report, 38 trial subjects have received both doses, and 100% (38/38) of them have achieved the immunogenicity with excellent safety and tolerability profile, with either or both humoral or cellular immune responses.
• Phase 1 data have suggested the vaccine could be a safe booster, and one of the volunteers in the 1.0mg dose group has become seropositive at baseline due to prior infection with COVID-19. Notably, despite receiving both doses, the individual has not developed any adverse events.
• Yet, the report highlights the need for a larger sample size and the inability to conclude the length of the vaccine-driven immunity.
• Early December, Inovio announced the initiation of the Phase 2 portion of Phase 2/3 trial for the vaccine in a trial involving 400 individuals aged 18 years or older.
• https://seekingalpha.com/news/3647358-inovio-is-up-9-in-premarket-on-peer-reviewed-data-for-covidminus-19-jab